(Q38286444)

1 September 2017

1 reference

title

Potential side effects to GLP-1 agonists: understanding their safety and tolerability (English)

1 reference

1 September 2017

Agostino Consoli

1

1 reference

1 September 2017

Gloria Formoso

series ordinal

2

1 reference

1 September 2017

language of work or name

English

0 references

publication date

12 December 2014

1 reference

Expert Opinion on Drug Safety

1 September 2017

published in

1 reference

1 September 2017

volume

14

1 reference

1 September 2017

issue

2

1 reference

1 September 2017

page(s)

207-218

1 reference

Novel GLP-1 receptor agonists for diabetes

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Recent advances in incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Exenatide extended-release: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

The efficacy and safety of liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Glucagon like peptide-1 receptor expression in the human thyroid gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Glucagon-like peptide-1 does not mediate amylase release from AR42J cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Exenatide (exendin-4)-induced pancreatitis: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Do GLP-1-based therapies increase cancer risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Treatment of type 2 diabetes with incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Incretin therapy and islet pathology: a time for caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Risk of pancreatitis in patients treated with incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.987122

10.1517/14740338.2015.987122

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference